Oppenheimer Lowers Enovix (NASDAQ:ENVX) Price Target to $21.00

Enovix (NASDAQ:ENVX) had its target price dropped by research analysts at Oppenheimer from $24.00 to $21.00 in a research report issued on Thursday, MarketBeat reports. The firm presently has an “outperform” rating on the stock. Oppenheimer’s target price points to a potential upside of 243.70% from the stock’s previous close.

A number of other brokerages have also recently commented on ENVX. TD Cowen reissued a “buy” rating on shares of Enovix in a research note on Thursday. Canaccord Genuity Group dropped their price objective on shares of Enovix from $21.00 to $15.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. B. Riley Financial dropped their price target on shares of Enovix from $17.00 to $10.00 and set a “buy” rating for the company in a research note on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enovix in a research note on Friday, April 10th. Finally, Wells Fargo & Company set a $6.00 price target on shares of Enovix in a research note on Thursday, March 12th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Enovix currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.64.

Enovix Stock Performance

Shares of NASDAQ:ENVX opened at $6.11 on Thursday. Enovix has a 52 week low of $4.61 and a 52 week high of $16.49. The stock has a market capitalization of $1.33 billion, a P/E ratio of -7.36 and a beta of 2.24. The firm has a fifty day simple moving average of $5.82 and a two-hundred day simple moving average of $7.10. The company has a quick ratio of 8.13, a current ratio of 8.34 and a debt-to-equity ratio of 1.90.

Enovix (NASDAQ:ENVX) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. Enovix had a negative net margin of 499.64% and a negative return on equity of 63.25%. The business had revenue of $7.60 million during the quarter, compared to analysts’ expectations of $6.95 million. During the same period last year, the company posted ($0.15) EPS. The business’s revenue was up 49.1% on a year-over-year basis. Enovix has set its Q2 2026 guidance at -0.170–0.130 EPS. On average, analysts expect that Enovix will post -0.81 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Enovix

Large investors have recently made changes to their positions in the company. Caitlin John LLC purchased a new position in shares of Enovix during the 3rd quarter worth about $27,000. Parallel Advisors LLC boosted its stake in shares of Enovix by 51.9% during the 3rd quarter. Parallel Advisors LLC now owns 3,926 shares of the company’s stock worth $39,000 after purchasing an additional 1,342 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in shares of Enovix during the 4th quarter worth about $30,000. CWM LLC lifted its holdings in Enovix by 95.4% during the 4th quarter. CWM LLC now owns 6,081 shares of the company’s stock valued at $44,000 after buying an additional 2,969 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new stake in Enovix during the 3rd quarter valued at about $80,000. 50.92% of the stock is owned by hedge funds and other institutional investors.

Key Enovix News

Here are the key news stories impacting Enovix this week:

• Positive Sentiment: Enovix’s Q1 results beat revenue expectations and the company reported a smaller-than-expected loss, while management highlighted revenue growth and strategic progress on the earnings call. Enovix Corp (ENVX) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Alignments
• Positive Sentiment: Unusually heavy call option activity suggests some traders are betting on a rebound in Enovix shares. Enovix (NASDAQ:ENVX) Price Target Cut to $21.00 by Analysts at Oppenheimer
• Neutral Sentiment: Oppenheimer, Benchmark, Craig Hallum, and TD Cowen all reduced their price targets on Enovix, but most still kept constructive ratings, signaling lower valuation expectations rather than a full thesis change. Enovix (NASDAQ:ENVX) Given New $15.00 Price Target at Benchmark Enovix (NASDAQ:ENVX) Price Target Lowered to $8.00 at Craig Hallum Enovix (NASDAQ:ENVX) Price Target Cut to $7.00 by Analysts at TD Cowen
• Negative Sentiment: Investors are also focused on Enovix’s widening losses and the uncertain timeline for commercialization, which appeared to weigh on the stock after earnings. Enovix sinks as losses widen; commercialization timeline remains in focus

Enovix Company Profile

Enovix Corporation (NASDAQ: ENVX) develops and manufactures advanced lithium-ion battery cells with a patented three-dimensional silicon-anode architecture. The company’s core focus is on delivering high energy density, improved safety, and longer cycle life compared to conventional graphite-based cells. Enovix’s technology targets a range of applications, including consumer electronics, wearable devices, electric vehicles and stationary energy storage systems.

Founded in 2011 and headquartered in Fremont, California, Enovix has built pilot production capability and is scaling up manufacturing capacity to meet growing demand.